… Sanofi India, and Sandeep Arora, Country Medical Director of AstraZeneca … India. They discussed the role of the pharmaceutical industry … government, academia, healthcare institutions, pharmaceutical companies and patient organisations …

New Delhi [India], March 4 (ANI): The DCGI (Drugs Controller General of India) on Wednesday issued an alert regarding a stolen batch of Sanofi India's insulin formulation, Lantus SoloStar (Insulin Glargine Injection IP, r-DNA origin, 100 IU/mL), with batch number 5F0347B. The consignment was stolen from Jagmohanpur, Odisha, while being transported to a Kolkata clearing and forwarding agent. According to the

Indian stock benchmarks ended little changed in a choppy session Thursday on subdued risk appetite, missing out on broad gains in global markets from Japan to Europe, where the benchmark index hit a record high. The Nifty 50 edged up 0.06% to 25,496.55 and the BSE Sensex shed 0.03% to 82,248.61. Both the benchmarks swung between gains of 0.4% and equivalent-sized losses over the course of Thursday’s session. They had added about 0.9% each intraday in the previous session as well, but surrendered most of those gains to finish only marginally higher on Wednesday. Fourteen of the 16 major sectors advanced on the day. Public sector banks added 1%, led by a 0.8% rise in the country’s largest lender State Bank of India after CLSA reiterated its “outperform” rating, citing an industry-leading liquidity coverage ratio, robust growth and profitability. The pharma index gained 1.1% on the day, taking its five-session rise to 3.9%, with analysts attributing the uptick to sector rotation. The highest-weighted stock in India’s stock benchmarks, private-sector lender HDFC Bank dropped 1%, offsetting the broader rise.

The new MD will define the company’s India strategy in alignment with Sanofi’s global strategy, besides driving priorities to accelerate innovation and agility throughout the organization

Sanofi India on Monday said it has appointed Deepak Arora as the company's new Managing Director. In this role, he will define and drive the strategic vision for India in alignment with Sanofi's global strategy, the company said in a statement. Arora will also spearhead strategic priorities to accelerate innovation and agility throughout the organisation, while fostering operational excellence across all functions, it added. He brings over 30 years of experience in the pharmaceutical and healthcare industry across North America, Europe, the Middle East and Africa. He has held leadership positions in Commercial, Sales & Marketing, and General Management roles, acquiring businesses and generating sustainable growth within several multinational companies. "His extensive pharmaceutical experience across diverse geographies aligns perfectly with our endeavour to serve patients throughout India," Aditya Narayan, Chairman of the Board, Sanofi India, said.

Indian conglomerate Reliance Industries is expected to post its Q2 earnings today.

Tata Capital to list on NSE and BSE today. The grey market premium suggests a lacklustre debut for India’s largest IPO

… and Innovation Head, Sanofi Consumer Healthcare India Limited said, “Having demonstrated … About Sanofi Consumer Healthcare India Limited Sanofi Consumer Healthcare India Limited (SCHIL … . Available at Resources for healthcare professionals - Sanofi India 5 …

Emcure Pharmaceuticals Ltd. ("Emcure") and Sanofi India Limited ("SIL… General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi … Office and Managing Director, Emcure Pharmaceuticals Ltd. "At Emcure, we …